B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
VTVT
vTv TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The supported bull case is narrow but real: cadisegliatin remains a late-stage asset with Breakthrough Therapy designation, CATT1 enrollment is guided for 3Q 2026, and company filings indicate financing plus the Newsoara payment should fund operations well past the expected topline window [#10-K-2026-03-10].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.8.
What can break
CATT1 enrollment or follow-up could slip, delaying the main value inflection beyond management's 3Q 2026 enrollment expectation [#10-K-2026-03-10].
Momentum
23
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $48.00 · Bear $18.00Analysis 2026-04-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $58.00
Why
Momentum23 · Δ7d +24.2
Value41 · Δ7d 0.0
Sentiment59 · Δ7d +2.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.8.
Contradictions & invalidation
- • CATT1 enrollment or follow-up could slip, delaying the main value inflection beyond management's 3Q 2026 enrollment expectation [#10-K-2026-03-10].
- • Cadisegliatin remains the dominant asset, so negative efficacy, safety, or regulatory feedback would likely have outsized downside impact.
- • The bear case is that VTVT is still effectively a single-asset, clinical-stage story with negative operating cash flow, explicit need for additional capital over time, and substantial dependence on timely CATT1 execution, enrollment, and eventual efficacy/safety readout [#10-K-2026-03-10].
Catalyst clock
2026-01-30
Balance-sheet de-risking from 2025 financing and Newsoara upfront payment
Lead driver: Sentiment · See AI snapshot
Momentum
23
9% active weight
Current posture
7d trendImproving
Δ7d
+24.2
Δ21d
+19.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
59
62% active weight
Current posture
7d trendImproving
Δ7d
+2.8
Δ21d
-3.2
Why this grade
Composite grade D. Momentum 23.5 / Value 41.2 / Sentiment 58.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-28. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$123.8M
Beta
0.50
Shares Out
3.95M
P/E (TTM) · Derived
-9.8
P/S (TTM)
9817.85
P/FCF (TTM) · Derived
-19.07
Rev YoY
-100.0%
EPS YoY
+14.6%
Gross Margin
+100.0%
Op Margin
-175382.4%
Net Debt
-$88.93M
Current Ratio
12.48
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data